Lecanemab treatment improves B cell subpopulation immune homeostasis in patients with Alzheimer's disease
Alzheimer's & Dementia · 2026
DOI: 10.1002/alz.71655 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2026. Verfasst von Yutong Cai und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Homeostasis, B-Lymphocyte Subsets, Antibodies, Monoclonal. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Brain Science and Brain-like Intelligence Technology-National Science and Technology Major Project, Lingang Laboratory.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Lecanemab, the first disease‐modifying therapy for Alzheimer's disease (AD), mitigates pathology primarily by clearing amyloid plaques, but its impact on peripheral immunity remains unclear. METHODS To assess Lecanemab's immunological effects, we performed antibody array analysis of serum and single‐cell RNA sequencing of peripheral blood mononuclear cells collected from healthy controls and patients with AD at baseline, 3, and 6 months post‐treatment. RESULTS Lecanemab restored multiple serum chemokines to healthy levels in patients with AD. Compared to controls, baseline samples from patients with AD showed altered frequencies and functions of naïve and unswitched memory (UswM) B cells. Lecanemab treatment corrected the abnormal naïve and UswM B cell proportions and rebuilt their functional homeostasis by alleviating chronic inflammation and reversing the dysregulation of key pathways including immune response, NF‐κB, RAGE, and cell adhesion. DISCUSSION These findings uncover a novel peripheral immunomodulatory mechanism of Lecanemab, offering new insights into AD therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.
- Institute of Clinical Neurology, Fujian Medical University, Fuzhou, China.
- Beijing Advanced Innovation Center for Biomedical Engineering, School of Engineering Medicine, Beihang University, Beijing, China.
- The School of Public Health, Fujian Medical University, Fuzhou, China.
- Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Neurology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China.
ORCID-Profile: Xiaochun Chen
Förderung
- National Natural Science Foundation of China
- Brain Science and Brain-like Intelligence Technology-National Science and Technology Major Project
- Lingang Laboratory
Zitieren
APA
Cai, Y., Wang, Y., Huang, W., Su, Y., Lei, M., Jia, R., Wu, C., Zhang, T., Sun, L., Peng, B., Cheng, J., Yu, J., Chen, X., Ye, Q., Yu, J., & Xin, J. (2026). Lecanemab treatment improves B cell subpopulation immune homeostasis in patients with Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1002/alz.71655
Vancouver
Cai Y, Wang Y, Huang W, Su Y, Lei M, Jia R, et al. Lecanemab treatment improves B cell subpopulation immune homeostasis in patients with Alzheimer's disease. Alzheimer's & Dementia. 2026. doi:10.1002/alz.71655
BibTeX
@article{Cai2026,
author = {Cai, Yutong and Wang, Yuxuan and Huang, Wenjing and Su, Ying and Lei, Ming and Jia, Ruonan and Wu, Chenyue and Zhang, Tianming and Sun, Lanlan and Peng, Bihao and Cheng, Jun and Yu, Jintai and Chen, Xiaochun and Ye, Qinyong and Yu, Jian and Xin, Jiawei},
title = {Lecanemab treatment improves B cell subpopulation immune homeostasis in patients with Alzheimer's disease},
journal = {Alzheimer's & Dementia},
year = {2026},
doi = {10.1002/alz.71655}
}
EUVIMED